Skip to main content
Erschienen in: Diabetology International 2/2015

01.06.2015 | Original Article

Factors associated with GAD antibody titer in subtypes of type 1 diabetes

verfasst von: Takumi Hirata, Akira Shimada, Jiro Morimoto, Taro Maruyama

Erschienen in: Diabetology International | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to compare factors associated with glutamic decarboxylase antibody (GADAb) titer between acute-onset and slowly progressive type 1 diabetes.

Research design and methods

We used a cross-sectional study to investigate 90 cases of GADAb-positive type 1 diabetes, including 40 acute-onset and 50 slowly progressive cases, to clarify factors associated with GADAb positivity in the two disease subtypes. We performed multivariate linear regression analysis to clarify factors associated with GADAb titer.

Results

In acute-onset cases, positive insulinoma-associated antigen-2 antibody (IA-2Ab) was negatively correlated with GADAb titer (β = −1.29, p = 0.048). In slowly progressive cases, GADAb titer was positively correlated with age (β = 0.05, p = 0.035) and positive thyroid autoantibodies (β = 1.59, p = 0.023), and negatively correlated with duration of diabetes (β = −1.34, p = 0.003). In slowly progressive cases, female gender (β = 1.65, p = 0.009) and age (β = 0.05, p = 0.048) were positively correlated, and duration of diabetes (β = −1.34, p = 0.004) and IA-2Ab positivity (β = −1.92, p = 0.029) were negatively correlated with GADAb titer only in cases with high GADAb titer.

Conclusions

GADAb titer was associated with autoimmune activity of pancreatic beta cells in acute-onset and slowly progressive cases with high GADAb titer, and duration of diabetes in slowly progressive cases.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tuomilehto J, Zimmet P, Mackay IR, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet. 1994;343:1383–5.PubMedCrossRef Tuomilehto J, Zimmet P, Mackay IR, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet. 1994;343:1383–5.PubMedCrossRef
2.
Zurück zum Zitat Batstra MR, Aanstoot HJ, Herbrink P. Prediction and diagnosis of type 1 diabetes using beta cell autoantibodies. Clin Lab. 2001;47:497–507.PubMed Batstra MR, Aanstoot HJ, Herbrink P. Prediction and diagnosis of type 1 diabetes using beta cell autoantibodies. Clin Lab. 2001;47:497–507.PubMed
3.
Zurück zum Zitat Zimmet P. Antibodies to glutamic acid decarboxylase in the prediction of insulin dependency. Diabetes Res Clin Pract. 1996;34(Suppl):S125–31.PubMedCrossRef Zimmet P. Antibodies to glutamic acid decarboxylase in the prediction of insulin dependency. Diabetes Res Clin Pract. 1996;34(Suppl):S125–31.PubMedCrossRef
4.
Zurück zum Zitat Yang L, Zhou ZG, Huang G, et al. Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. World J Gastroenterol. 2005;11:2900–5.PubMedCentralPubMedCrossRef Yang L, Zhou ZG, Huang G, et al. Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. World J Gastroenterol. 2005;11:2900–5.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Buzzeti R, Di Pietro S, Giaccari A, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007;30:932–8.CrossRef Buzzeti R, Di Pietro S, Giaccari A, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007;30:932–8.CrossRef
6.
Zurück zum Zitat van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabetes Med. 2008;25:117–25.CrossRef van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabetes Med. 2008;25:117–25.CrossRef
7.
Zurück zum Zitat Lee SA, Lee WJ, Kim EH, et al. Progression to insulin deficiency in Korean patients with Type 2 diabetes mellitus positive for anti-GAD antibody. Diabetes Med. 2011;28:319–24.CrossRef Lee SA, Lee WJ, Kim EH, et al. Progression to insulin deficiency in Korean patients with Type 2 diabetes mellitus positive for anti-GAD antibody. Diabetes Med. 2011;28:319–24.CrossRef
8.
Zurück zum Zitat Kawasaki E, Maruyama T, Imagawa A, et al. Proposal of diagnostic criteria for acute-onset type 1 diabetes mellitus (2012)—report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus. J Jpn Diabetes Soc. 2013;56:584–9. Kawasaki E, Maruyama T, Imagawa A, et al. Proposal of diagnostic criteria for acute-onset type 1 diabetes mellitus (2012)—report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus. J Jpn Diabetes Soc. 2013;56:584–9.
9.
Zurück zum Zitat Savola K, Bonifacio E, Sabaah E, et al. IA-2 antibodies—a sensitive marker of IDDM with clinical onset in childhood and adolescence: Childhood Diabetes in Finland Study Group. Diabetologia. 1998;41:424–9.PubMedCrossRef Savola K, Bonifacio E, Sabaah E, et al. IA-2 antibodies—a sensitive marker of IDDM with clinical onset in childhood and adolescence: Childhood Diabetes in Finland Study Group. Diabetologia. 1998;41:424–9.PubMedCrossRef
10.
Zurück zum Zitat Gabbay MA, Sato MN, Duarte AJ, Dib SA. Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol. 2012;168:60–7.PubMedCrossRef Gabbay MA, Sato MN, Duarte AJ, Dib SA. Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol. 2012;168:60–7.PubMedCrossRef
11.
Zurück zum Zitat Harrison LC, Honeyman MC, DeAizpurua HJ, et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet. 1993;341(8857):1365–9.PubMedCrossRef Harrison LC, Honeyman MC, DeAizpurua HJ, et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet. 1993;341(8857):1365–9.PubMedCrossRef
12.
Zurück zum Zitat Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314:1360–8.PubMedCrossRef Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314:1360–8.PubMedCrossRef
13.
Zurück zum Zitat Sosenko JM, Skyler JS, Palmer JP, et al. A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care. 2011;34:2435–7.PubMedCentralPubMedCrossRef Sosenko JM, Skyler JS, Palmer JP, et al. A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care. 2011;34:2435–7.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Yokota I, Matsuda J, Naito E, et al. Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. Diabetes Care. 1998;21:49–52.PubMedCrossRef Yokota I, Matsuda J, Naito E, et al. Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. Diabetes Care. 1998;21:49–52.PubMedCrossRef
15.
Zurück zum Zitat Rattarasarn C, Diosdado MA, Ortego J, et al. Thyroid autoantibodies in Thai type 1 diabetic patients: clinical significance and their relationship with glutamic acid decarboxylase antibodies. Diabetes Res Clin Pract. 2000;49:107–11.PubMedCrossRef Rattarasarn C, Diosdado MA, Ortego J, et al. Thyroid autoantibodies in Thai type 1 diabetic patients: clinical significance and their relationship with glutamic acid decarboxylase antibodies. Diabetes Res Clin Pract. 2000;49:107–11.PubMedCrossRef
16.
Zurück zum Zitat Bárová H, Perusicová J, Hill M, et al. Anti-GAD positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiol Res. 2004;53:279–86.PubMed Bárová H, Perusicová J, Hill M, et al. Anti-GAD positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiol Res. 2004;53:279–86.PubMed
17.
Zurück zum Zitat Hamaguchi K, Kimura A, Kusuda Y, et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res Clin Pract. 2004;66:163–71.PubMedCrossRef Hamaguchi K, Kimura A, Kusuda Y, et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res Clin Pract. 2004;66:163–71.PubMedCrossRef
18.
Zurück zum Zitat Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62:543–50.PubMedCentralPubMedCrossRef Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62:543–50.PubMedCentralPubMedCrossRef
Metadaten
Titel
Factors associated with GAD antibody titer in subtypes of type 1 diabetes
verfasst von
Takumi Hirata
Akira Shimada
Jiro Morimoto
Taro Maruyama
Publikationsdatum
01.06.2015
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 2/2015
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-014-0181-z

Weitere Artikel der Ausgabe 2/2015

Diabetology International 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.